The University of Tokyo

Tokyo Institute of Technology

Nanocarrier Co., Ltd.

Nof Corporation

Tokyo Medical and Dental University

Toudai Tlo, Ltd.

Osaka University

Riken Corporation

Japan Science and Technology Corporation

Keio University

National Cancer Center

Sbi Pharmaceuticals Co., Ltd.

Transparent Inc.

Stella Pharma Corporation

Nobuhiro Nishiyama

Kazunori Kataoka

Kanjiro Miyata

Hiroyasu Takemoto

Takahiro Nomoto

Makoto Matsui

Yasuki Kato

Keishiro Tomoda

Hiroki Yoshioka

Takehiko Ishii

Shigeto Fukushima

Atsushi Ishii

Keiji Itaka

Yutaka Miura

HyunJin Kim

Horacio Cabral

Yu Matsumoto

Kazuki Osakama

Yuji Yamamoto

Naoki Yamada

Takanori Yokota

Masataka Nakanishi

Satoru Matsumoto

Kazutaka Nishina

Hidehiro Mizusawa

Masaki Kamiya

Yasutaka Anraku

Midori Hirai

Kensuke Osada

Hiroyuki Chaya

Makoto Oba

Sumiyo Watanabe

Ken Hamura

Tatsuyuki Hayashi

Shourong Wu

Yu Fukusato

Akihiro Mizoguchi

Hiroya Kuwahara

Akiko Sasaki

Kazuki Miyauchi

Yan Lee

Masayuki Yokoyama

Daisuke Ohno

Takuzo Aida

Naoya Shibata

Masaki Mori

Yuichi Tei

Yasuhiro Matsumura

Akihiro Kishimura

Takuya Hashimoto

Masahiro Yasunaga

Hideki Shimizu

Shino Manabe

Hideyuki Saya

Soichiro Okazaki

Yuichi Yamasaki

Mika Hamura

Tsuneo Saga

Naoki Kanayama

Osamu Nagano

Tomoya Suma

Chieko Tsuchiya

Hideshi Ishii

Hiroyuki Koyama

Yuto Honda

Ichio Aoki

Ryo Tsumura

Hiroaki Kinoh

Ronald James Christie

Yuichi Hori

Toshiro Fujita

Shinya Kaname

Wenjie Wang

Shinsuke Ohba

Ung-il Chung

Woo-Dong Jang

Shunsaku Asano

Dong-Lin Jiang

Hendrick Stapert

Yukiya Inoue

Ying Yao

Kaito Kanamori

Masamitsu Konno

Takanori Inaba

Xiaohang Sun

Kana Kohmoto

Abdul-Hackam Ranneh

Kenji Tsuchihashi

Tsukasa Nishimori

Tsukasa Chida

Yoshikatsu Koga

Yoshiyuki Yamamoto

Ryuta Sato

Peng Mi

Daisuke Kokuryo

Kentaro Suina

Shigehiro Hiki

Mai Sanjo

A conjugate is provided in which a deferoxamine-type compound, which is at least one compound selected from the group consisting of deferoxamine or an ion or salt thereof, and a derivative thereof, and a biocompatible polymer are conjugated, where the biocompatible polymer contains a first biocompatible polymer chain and a second biocompatible polymer chain that is different from the first biocompatible polymer chain.

Conjugate and cancer therapeutic agent

A branched degradable polyethylene glycol derivative with a high molecular weight that does not cause vacuolation of cells is provided. A branched degradable polyethylene glycol derivative represented by the following formula (1), containing, in a molecule, an oligopeptide that is degraded in the cells: wherein kand kare each independently 1-12, jand jare each independently 45-950, R is a hydrogen atom, a substituted or unsubstituted alkyl group having 1-12 carbon atoms, a substituted aryl group, an aralkyl group or a heteroalkyl group, Z is an oligopeptide that is degraded by enzyme in the cells, X is a functional group capable of reacting with a bio-related substance, and Land Lare each independently a single bond or a divalent spacer.

Asymmetrically branched degradable polyethylene glycol derivative

A multi-arm, degradable polyethylene glycol derivative with a high molecular weight that does not cause vacuolation of cells is provided. A degradable polyethylene glycol derivative represented by the following formula (1): wherein n1 and n2 are each independently 45-950, Wand Ware each independently an oligopeptide of 2-47 residues, a1 and a2 are each independently 1-8, Q is a hydrocarbon chain having 2-12 carbon atoms and optionally containing an oxygen atom and/or a nitrogen atom, Xand Xare each independently a functional group capable of reacting with a bio-related substance, and L, L, L, L, Land Lare each independently a divalent spacer.

Degradable multi-arm polyethylene glycol derivative

A bio-related substance bonded to a branched and degradable polyethylene glycol derivative that is degraded in the cells represented by the following formula (A): wherein each symbol is as defined in the present specification, is provided by the present invention.

Branched degradable polyethylene glycol binder

The invention provides a bio-related substance bonded to a high-molecular-weight polyethylene glycol derivative that does not cause vacuolation of cells. The bio-related substance bonded to a degradable polyethylene glycol derivative is represented by the formula (A): wherein m is 1-7, n1 and n2 are each independently 45-682, p is 1-4, R is an alkyl group having 1-4 carbon atoms, Z is an oligopeptide with 2-8 residues composed of neutral amino acids excluding cysteine, Q is a residue of a compound having 2-5 active hydrogens, D is the bio-related substance, L1, L2, L3, L4 and L5 are each independently a single bond or a divalent spacer, and y is 1-40.

Degradable polyethylene glycol conjugate

The invention provides a high-molecular-weight polyethylene glycol derivative that does not cause vacuolation of cells. The degradable polyethylene glycol derivative is represented by the following formula (1): wherein m is 1-7, n1 and n2 are each independently 45-682, p is 1-4, R is an alkyl group having 1-4 carbon atoms, Z is an oligopeptide with 2-8 residues composed of neutral amino acids excluding cysteine, Q is a residue of a compound having 2-5 active hydrogens, X is a functional group capable of reacting with a bio-related substance, and L, L, L, Land Lare each independently a single bond or a divalent spacer.

Degradable polyethylene glycol derivative

A pH-responsive polymer formed of a biocompatible polymer to which a group which is electrically neutral under pH environments of more than 7 and which changes to be cationic at pH 7 or less is bonded.

PH-responsive polymer and drug delivery system

The present invention pertains to a ligand that contains a plurality of groups represented by formula (1) and is capable of multivalently binding to a glutamine transporter expressed in excess in a cancer cell compared to a normal cell.

Ligand capable of multivalently binding to glutamine transporter, and composition comprising same

The present invention pertains to: a p-boronophenylalanine derivative that comprises a polymer to which a group represented by formula (I) is linked directly or via a linker; a composition containing same; and a kit for producing said derivative and composition.

P-boronophenylalanine derivative and composition containing same, and kit for producing said derivative and composition

The present invention is directed to provide antitumor agent including water-soluble sulfasalazine as an active ingredient. Antitumor agents were obtained with, as the water-soluble sulfasalazine, a PEG-modified sulfasalazine represented by the following formula: wherein an average value of n is 4 or larger and 1136 or smaller.

Antitumor agent

A unit structure-type pharmaceutical composition includes a single nucleic acid, such as an antisense nucleic acid, electrostatically bound to a single block copolymer having a cationic polyamino acid segment and a hydrophilic polymer chain segment. The negative charges of the nucleic acid are counterbalanced, at least substantially, by the positive charges of the cationic polyamino acid segment such that the pharmaceutical composition is electrically neutral or nearly electrically neutral. Further, the nucleic acid is covered with the hydrophilic polymer chain segment. The block copolymer thereby improves the blood retention capability of the nucleic acids.

Unit structure-type pharmaceutical composition for nucleic acid delivery

The present invention provides a vesicle, a conjugate, a composition comprising the vesicle or the conjugate, for use in delivering a drug to the brain, and a method for administering the same. The composition of the present invention is a composition for administration to a subject according to a dosing regimen, comprising a carrier for drug delivery, wherein the dosing regimen comprises administering the composition to a subject who has been fasted or caused to have hypoglycemia and inducing an increase in blood glucose level in the subject, and the carrier is modified at the outer surface thereof with a GLUT1 ligand.

Carrier for use in delivering drug, conjugate, composition comprising same, and method for administrating same

The problem addressed by the present invention is to develop a pharmaceutical having therapeutic efficacy against epirubicin-resistant tumors. The present invention provides a micelle having an anti-cancer agent disposed inside the core of the micelle formed by an epirubicin-conjugated copolymer.

Micelle containing epirubicin-complexed block copolymer and anti-cancer agent, and pharmaceutical composition containing said micelle applicable to treatment of cancer, resistant cancer or metastatic cancer

Monoclonal antibodies against human and mouse tissue factor, and fragments thereof, are disclosed, as well as pharmaceutical compositions and compositions for drug delivery containing the same. Therapeutic methods using the same are also disclosed.

Anti-tissue factor monoclonal antibody

Growing community of inventors

Tokyo, Japan

Nobuhiro Nishiyama